Top Banner
PRIVATE EQUITY ANGEL INVESTOR VENTURE CAPITA VENTURE CA SEED FUND GRANTS SERIES A IPO MERCHANT BANKER GRANTS MEZZANINE FINANCE PRIVATE EQUITY INVESTOR FINANCE SERIES B Opportunies IDENTIFY NEW FUNDING In Cancer Drug Development Copyright © HH Biotechnologies Pvt. Ltd.
6

Oncology Drug Funding 2013 - A Comprehensive Report on Cancer Drug Funding.

Jan 16, 2015

Download

Economy & Finance

Team OmicsX

Oncology Drug Funding is first of its kind funding intelligence report, which provides complete landscape on cancer drug funding starting from early, mid to late stage funding. Released in Sep 2013, it is largest focused updated data available, covering 321 active cancer-focused investors, with past 10 years investment details in more than 500 oncology-focused companies.

Thus It will help to
- First innovative report to provide insights on several new strategic/financial investors willing to fund your company’s growth.
- Clearly identify - who will invest in your business and to which extent.
- Quickly navigate the complete profiles of new and focused Investors and their investment strategies.
- Identify the extent of funding in each round/series to meet your immediate and future needs.
- To design and negotiate on better financial plans to unlock the real value of innovation/assets.
- Directly get in touch with oncology focused Venture Partner through their Linkedin & E-mail ID.
- Explore Top Investors and eliminate your hours of digital search and data curation.
- Access to Numerous deals, structure & size to analyze true value of business model.
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Oncology Drug Funding 2013 - A Comprehensive Report on Cancer Drug Funding.

PRIVATE EQUITY

ANGEL INVESTOR VENTURE CAPITAL

VENTURE CAPITALSEED FUND GRANTSSERIES A

IPOMERCHANT BANKERGRANTSMEZZANINE FINANCEPRIVATE EQUITY

INVESTOR

FINANCE

SERIES B

OpportunitiesIDENTIFY NEW FUNDING

In Cancer Drug Development

Copyright © HH Biotechnologies Pvt. Ltd.

Page 2: Oncology Drug Funding 2013 - A Comprehensive Report on Cancer Drug Funding.

A Comprehensive Intelligence Report On

ONCOLOGY DRUGFUNDING

2013

REPORT COVERS ‘ONCOLOGY FOCUSED’

3215029473000+

Active Venture Capital Firm Profiles

Investment Size | Criteria | Geographic focus

Company Funding Details

Includes past 10 years all Major Investment Rounds/Series

Venture Partners Professional Profiles

Linkedin & Email IDs of Partners | Personal Assistants Email IDs / Contact details

Funding Round Details

Details of Series A | B | C | D | E | F Included

Infographics Based Summary

Quick explore the Geographic distribution of VCs & their Geographic preference of

funding w.r.t USA, Europe & Asia.6 pages

VENTURE CAPITALPRIVATE EQUITY

PRIVATE EQUITY

ANGEL INVESTOR VENTURE CAPITAL

VENTURE CAPITALSEED FUND

GRANTSSERIES AMERCHANT BANKER GRANTS MEZZANINE FINANCE

FINANCEIPO

COMPREHENSIVE INTELLIGENCE SERIES2

Copyright © HH Biotechnologies Pvt. Ltd.

Page 3: Oncology Drug Funding 2013 - A Comprehensive Report on Cancer Drug Funding.

2013

Oncology Drug Funding 2013 is first of its kind funding intelligence report, which provides complete

landscape on cancer drug funding starting from early, mid to late stage fundings. It brings more

authentic data under evaluation and is designed in a manner to keep knowledge intact, clear and

precise. It also offers quick navigation on past 10 years major investments in the domain, thus allowing

the information on fingertips’ and enhances your drug funding in-depth understanding. Further any

information duplication is avoided to provide you with a clear and actionable intelligence.

Full Coverage

•    One of the largest updated data available, covering 321 active cancer-focused investors with their investment

details in more than 500 oncology-focused companies.

•    Includes Active Venture Capital, Private Equity and some notable Angel Investor firms.

•    Also includes individual Investor Company profile, their core oncology venture partner team details &

Investor funding preferences & past investments.

Complete Cancer Drug Investors Intelligence

•    With quick navigation tables, easily identify the top investors and their rich investment portfolio.

•    Identify where large investors are investing in; and easily predict their funding preferences.

•    Within oncology funding space, identify individual investor’s inclination towards funding drugs, diagnostics

or risky technologies.

Identify Top Investors

•    Worldwide coverage of 500+ companies including cancer drug discovery/development, cancer diagnostic

and cancer device/technology companies.

•    Past 10 years complete funding data including various follow-up funding round/series details.

•    Navigation Table to identify various funding Exits; through IPO or M&A activities.

•    Quick all sets of funding from Seed to Growth are covered.

All at One Place

PRIVATE EQUITYVENTURE CAPITAL

ANGEL INVESTORVENTURE CAPITAL

PRIVATE EQUITY

PRIVATE EQUITY

VENTURE CAPITALSEED FUND

MERCHANT BANKERSEED FUND

SEED FUND

FINANCE

MERCHANT BANKER

PARTNER

FINANCE

GRANTSGRANTS

MEZZANINE FINANCEIPOSERIES B

SERIES AIPO

GROWTH FUND SERIES AMERCHANT BANKER

Largest Oncology Funding Database with

Oncology focused Venture Partner’s Profiles.

3ONCOLOGY DRUG

FUNDING

Copyright © HH Biotechnologies Pvt. Ltd. www.omicsx.com/reports.html

Page 4: Oncology Drug Funding 2013 - A Comprehensive Report on Cancer Drug Funding.

12 Pages Infographics and Table,

describes worldwide distribution

of 321 Active Oncology Drug

Funding Firms, with their

country wise location, assets

size, geographic investment

preferences, ideal investment

range and investment focus

towards –early, mid and late stage

funding.

33 Pages Infographics and Tables,

provides the complete insights of

oncology funding pattern in past

10 years in 449 cancer focused

companies, with geographic

emphasis on investments in Exit

(through IPO/M&A) and Active

companies. Navigation tables

for Exit and Active companies to

provide list of all major funding

rounds and their investors.

502 Pages contain 321 active

oncology focused investor firms

profiles covering details of contact,

Funds under management, Total

investment portfolio Vs. cancer

focused investment portfolio,

geographic investment preference

and investment range.

Individual Firm management

profiles of key oncology focused

venture partners, e-mail/LinkedIn

contact details. Firm’s all major

oncology focused investments,

series/rounds details with list of

co-investors.

SECTIONSECTION

SECTIONSECTION

SECTIONSECTIONReport StructuresThe complete 570 pages report is divided in three main sections

for easy and quick navigation within report. Report sections

contains thousands of interlinks to reach desired information

on a single click. Apart, Table A.1, B.1 & B.2 are quite beneficial

in narrowing down the choice of investors and identifying

individual companies funding history.

VENTURE CAPITALPRIVATE EQUITY

PRIVATE EQUITY

ANGEL INVESTOR VENTURE CAPITAL

VENTURE CAPITALSEED FUND

GRANTSSERIES AMERCHANT BANKER GRANTS MEZZANINE FINANCE

FINANCEIPO

COMPREHENSIVE INTELLIGENCE SERIES4

Copyright © HH Biotechnologies Pvt. Ltd.

Page 5: Oncology Drug Funding 2013 - A Comprehensive Report on Cancer Drug Funding.

How this Report can Help

PRIVATE EQUITYVENTURE CAPITAL

ANGEL INVESTORVENTURE CAPITAL

PRIVATE EQUITY

PRIVATE EQUITY

VENTURE CAPITALSEED FUND

MERCHANT BANKERSEED FUND

SEED FUND

FINANCE

MERCHANT BANKER

PARTNER

FINANCE

GRANTSGRANTS

MEZZANINE FINANCEIPOSERIES B

SERIES AIPO

GROWTH FUND SERIES AMERCHANT BANKER

•    First innovative report to provide insights on several new strategic/financial investors willing to fund your

company’s growth.

•    Identify key venture partners contribution and strategic positions on Company’s Board.

•    Detailed series co-investors details to identify best investors consortium for your needs.

•    Access to Numerous deals, structure & size to analyze true value of business model.

CXOs / Directors / VPs

•    Identify new emerging players in drug funding, with their core team and funding preferences.

•    De-risk the venture by getting real insights through a comprehensive picture.

•    Infographics design with focused and interactive content, takes no time in filling knowledge gaps.

•    Virtually cover all oncology focused funding deals occurs in past 10 years with their valuation sizes.

Venture Partners

•    Clearly identify - who will invest in your business and to which extent.

•    Quickly navigate the complete profiles of focused Investors and their investment strategies.

•    Identify the extent of funding in each round/series to meet your immediate and future needs.

•    To design and negotiate on better financial plans to unlock the real value of innovation/assets.

•    Directly get in touch with oncology focused Venture Partner through Linkedin & E-mail ID.

Start-ups / Entrepreneurs

•    Explore Top Investors and eliminate your hours of digital search and data curation.

•    Spend quality time in analyzing finer funding details & decisions making.

•    Identify paradigm shift in oncology drug funding; with 10 years of funding history covering 500+ companies

and 3000+ Deals.

•    Closely monitor wining deals and M&A activities by bringing more data under analysis.

Analysts/ Consultants

A Perfect Guide to provide complete

Landscape on Oncology Drug Funding.

5ONCOLOGY DRUG

FUNDING

Copyright © HH Biotechnologies Pvt. Ltd. www.omicsx.com/reports.html

Page 6: Oncology Drug Funding 2013 - A Comprehensive Report on Cancer Drug Funding.

VENTURE CAPITALPRIVATE EQUITY

PRIVATE EQUITY

ANGEL INVESTOR VENTURE CAPITALPRIVATE EQUITY

VENTURE CAPITALSEED FUND

GRANTSSERIES A

IPOMERCHANT BANKER GRANTS MEZZANINE FINANCE

FINANCEIPO

YES, I WOULD LIKE TO PURCHASE NOW

Your Details: (Please use BLOCK CAPITALS)

Title: Dr Mr Ms

First Name:__________________________________________________

Last Name:___________________ Middle Name:____________________

Department:_________________________________________________

Position:_____________________________________________________

Company:____________________________________________________

Address:_____________________________________________________

___________________________________________________________

____________________________State/Province___________________

Country:_____________________Postcode/Zip:____________________

Tel:____________________________ Fax:_________________________

Mobile No:__________________________________________________

Email:_______________________________________________________

Please sign below to confirm your order

Date: ___________ Signature______________________________________

Product Type: Intelligence Report (570 pages)Published by: HH Biotechnologies Pvt. Ltd.

Product Code: ODF2013 Published in: September 2013

Single user price: $1495.00Online Purchases: Click Here

PaymentTo pay by Credit Card (PayPal, Visa, MasterCard, American Express), please, click ‘BUY NOW’ button on repot page http://omicsx.com/reports.html

Mail this completed order form to: HH Biotechnologies Pvt. Ltd. 2760,Link Road,Nunhai Industrial Area,Near Rambagh,Agra-282006 India.E-mail: [email protected] Online: www.omicsx.com

Fax back this form toUSA +1 646 568 9962 Asia +91 562 228 1099

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: [email protected]

Stay Legal: Terms & Conditions In placing an order you agree not to hand-on or otherwise communicate this report in whole or part to any 3rd partywhatsoever by any means or any access. You firstly pay for report, then I provide it.

Our full terms and conditions related to the sale of this report please click here....

(All orders must be signed by authorised signatory)

Sales Contact NumbersUSA +1 646 513 4433 UK +44 203 608 3536Asia +91 562 228 1122

Product Name: A Comprehensive Intelligence Report On - Oncology Drug Funding 2013

Order FOrm

Copyright © HH Biotechnologies Pvt. Ltd.